Description: Advanced Solid Tumors: ABBV-400 as Monotherapy-A Global First-in-Human Study Mechanism of Action: Antibody drug conjugate targeting c-MET with a topoisomerase inhibitor payload Target Patient Population: All solid tumors Study Design: Study drug is administered IV every 3 weeks For more information on this trial, read its profile on clinicaltrials.gov here.
C-1400-01 (AGEN1777) (Agenus, Inc.) Description: A Phase 1 Study Investigating AGEN1777 as a Single-Agent and in Combination with PD-1 Inhibition in Patients With Advanced Solid Tumors Mechanism of Action: bispecific antibody targeting TIGIT and CD96 (to enhance T and NK cell activation) Target Population: All solid tumors. To be given as single agent or in
ALKS 4230-003 (Alkermes Inc. ) Description: Clinical and Immunologic Activity of Nemvaleukin Alfa With a less Frequent IV Dosing With Pembrolizumab and Impact on Tumor Microenvironment in Soloid Tumor Patients (Artistry-3) Mechanism of Action: IL2 receptor agonist Target Patient Population: Cutaneous melanoma, Renal Cell, Triple Negative Breast, MMS Colorectal, Ovarian and any MSI-High solid tumors
AT148002 (ALX Oncology) Description: A Phase 1/2 Study of ALX148 in Combination with Azacitidine in Patients with Higher Risk Myelodysplastic Syndrome (MDS) Mechanism of Action: ALX148 is a CD47 blocker. Target Patient Population: High Risk MDS Study Design: Study Drug will be administered IV every 2 or 4 weeks. Combination drug, Azacitidine given as would
A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS) Principal Investigator: Dr. Brett Brinker For more information on this trial, read its profile on clinicaltrials.gov here.
ALPN-202 – NEON-1 (Alpine Immune Sciences) Description: An open-Label Study of ALPN-202 In Subjects With Advanced Malignancies (NEON-1) Mechanism of Action: Inhibits PDL1 and CTLA4, engages CD28 co-stimulator. Target Patient Population: Currently in expansion for Melanoma, Renal cell and PDL1 positive cancers only Study Design: Study drug is administered IV every 1 or 3 weeks
ALPN-202 – NEON-2 (Alpine Immune Sciences) Description: An open-Label Study of ALPN-202 Combined With PD-1 Inhibition In Subjects With Advanced Malignancies (NEON-2) Mechanism of Action: Inhibits PDL1 and CTLA4, engages CD28 co-stimulator in combination with Pembrolizumab. Target Patient Population:. All solid tumors Study Design: Study drug is administered IV every 1 or 3 weeks
A Phase III Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterized by PTEN deficiency (CAPItello-281) Principal Investigator: Dr. Eric Batts For more information on this trial, read its profile on clinicaltrials.gov here.
A Phase II Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of AZD0171 in Combination with Durvalumab and Chemotherapy in Participants with Locally Advanced or Metastatic Solid Tumours PI: Dr. Chandana Available at: CHCWM – Muskegon, Holland Cancer Center, Lacks Cancer Center at Saint Mary’s, Lemmen-Holton Cancer Pavilion For more information on this